Abstract:Proteolysis targeting chimera (PROTAC) technology, a groundbreaking strategy for degradation of pathogenic proteins by hijacking of the ubiquitin-proteasome-system has become a promising strategy in drug design. However, the real-time monitoring and visualization of protein degradation processes have been long-standing challenges in the realm of drug development. In this research, we sought to amalgamate the highly efficient protein-degrading capabilities of PROTAC technology with the visualization attributes of fluorescent probes, with the potential to pave the path for the design and development of a novel class of visual PROTACs. These novel PROTACs uniquely possess both fluorescence imaging and therapeutic characteristics, all with the goal of enabling real-time observations of protein degradation processes. Our approach involved the utilization of a high ER-targeting fluorescent probe, previously reported in our laboratory, which served as a warhead that specifically binds to the protein of interest (POI). Additionally, a VHL ligand for recruiting E3 ligase and linkers of various lengths were incorporated to synthesize a series of novel ER-inherent fluorescence PROTACs. Among them, compound A3 demonstrated remarkable efficiency in degrading ERα proteins (DC 50 = 0.12 μM) and displaying exceptional anti-proliferative activity against MCF-7 cells (IC 50 = 0.051 μM). Furthermore, it exhibited impressive fluorescence imaging performance, boasting an emission wavelength of up to 582 nm, a Stokes shift of 116 nm, and consistent optical properties. These attributes make it especially suitable for the real-time, in situ tracking of ERα protein degradation processes, thus may serve as a privileged visual theranostic PROTAC for ERα + breast cancer. This study not only broadens the application spectrum of PROTAC technology but also introduces a novel approach for real-time visualization of protein degradation processes, ultimately enhancing the diagnostic and treatment efficacy of PROTACs.

Glutathione-responsive PROTAC for targeted degradation of ERα in breast cancer cells

Engineering POLYTAC Nanoparticles for Bioorthogonal Click Reaction-Enforced Protein Degradation and Breast Cancer Therapy

Glutathione-Scavenging Nanoparticle-Mediated PROTACs Delivery for Targeted Protein Degradation and Amplified Antitumor Effects

PROTAC Degrader of Estrogen Receptor Α Targeting DNA-Binding Domain in Breast Cancer.

Development of Stabilized Peptide-Based PROTACs Against Estrogen Receptor Α

Discovery of estrogen receptor α targeting caged hypoxia-responsive PROTACs with an inherent bicyclic skeleton for breast cancer treatment

Fluorescence theranostic PROTACs for real-time visualization of ERα degradation

A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapy

Selective degradation of BRD4 suppresses lung cancer cell proliferation using GSH-responsive PROTAC precursors

Development of Cell-Permeable Peptide-Based PROTACs Targeting Estrogen Receptor Α

Hydrogen Peroxide-Inducible PROTACs for Targeted Protein Degradation in Cancer Cells

Targeting estrogen receptor α for degradation with PROTACs: A promising approach to overcome endocrine resistance

Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras Through Irgd Peptide Conjugation: A Strategy for Precise Protein Degradation in Breast Cancer.

Proteolysis targeting chimera extracellular vesicles for therapeutic development treating triple negative breast cancer

Design and Synthesis of Proteolysis-Targeting Chimeras (protacs) As Degraders of Glutathione Peroxidase 4.

Discovery of a Novel Class of PROTACs As Potent and Selective Estrogen Receptor Α Degraders to Overcome Endocrine-Resistant Breast Cancer in Vitro and in Vivo

Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy

Enzyme-catalyzed Activation of Pro-PROTAC for Cell-selective Protein Degradation

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Glutathione-dependent degradation of SMARCA2/4 for targeted lung cancer therapy with improved selectivity

Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC